Targeting Chromothripsis in Malignant Glioma
Abstract
Clinical biomarker detection has paved the way in determining the patient population that will most benefit from a specific treatment. In this way, there will be fewer unnecessary side effects as a patient determined as a non-responder via biomarker presence or absence would not be selected to receive this treatment. A classic example is the expression of the HER2 receptor in breast cancers. If a patient is HER2 positive, they will receive the HER2-targeting drug, Herceptin. However, a non-HER2 positive patient would not receive Herceptin as they do not have the drug target expressed. Here, HER2 is a positive selection biomarker that dictates treatment therapeutic options to prevent over-treatment and assist in positive patient selection. While other cancers, like breast, have well-defined biomarkers that dictate drug options, the brain cancer glioblastoma (GBM) is lagging. GBM is the most common and deadly brain cancer in adults with an average survival post-diagnosis of tilde14-16 months. This survival time greatly decreases once a patient becomes resistant to the current first line therapeutic option - temozolomide (TMZ). For these reasons, we are proposing to elucidate a biomarker of TMZ-resistant GBM, as well as better understand the disease, to determine the best second line therapeutic option for these patients.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2023
- Accession Number
- AD1217541
Entities
People
- Deanna Tiek
Organizations
- Northwestern University